New drug tested to keep aggressive lung cancer at bay
NCT ID NCT04418648
Summary
This study tested whether adding the drug toripalimab after standard chemoradiation could help control limited-stage small cell lung cancer longer. It involved 170 patients whose cancer hadn't worsened after initial treatment. The trial was terminated before completion, so full results aren't available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER LIMITED STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, 510060, China
Conditions
Explore the condition pages connected to this study.